DNMT3A and breast cancer: MiR-194 targeted DNMT3A in BC, and the increased expression of miR-194 stimulated tumor suppressor cyclin G2, p27Kip1 and ADAM metalpeptidase domain 23 (ADAM23), leading to inhibited cell motility [97].